Levamisole in childhood idiopathic nephrotic syndrome: new promises, and advocacy for global access.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38642993.
- Also identified by DOI 10.1016/j.kint.2024.01.030.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the current issue of Kidney International, Sinha et al. present data from an open-label, noninferior, randomized controlled trial comparing 12-months of alternate-day prednisolone, given daily during infection, versus levamisole, in children with frequently relapsing or steroid-dependent nephrotic syndrome. This study suggests that both of these strategies are efficacious and safe. Results of this study should redefine the role of levamisole in future guidelines, and a call for global availability of levamisole should be advocated.
Medical subject headings
- Levamisole
- Nephrotic Syndrome